Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 15/20 | 0.64 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.47 |
| ▸ | KHK | P50053 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | ROS1 | P08922 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | MARK3 | P27448 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 0.43 |
| ▸ | STK3 | Q13188 | 1/20 | 0.43 |
| ▸ | MELK | Q14680 | 1/20 | 0.43 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.43 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.43 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.43 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4779796 | 0.87 | AKT1 (0.65) | AKT1LIMK2KHKLRRK2CDC7 | |
| SCHEMBL4727205 | 0.81 | AKT1 (0.73) | AKT1LIMK2 | |
| SCHEMBL4779777 | 0.80 | AKT1 (0.59) | AKT1LIMK2KHKLRRK2 | |
| SCHEMBL4778772 | 0.79 | AKT1 (0.62) | AKT1LIMK2 | |
| SCHEMBL4776365 | 0.78 | AKT1 (0.68) | AKT1 | |
| SCHEMBL4909196 | 0.78 | AKT1 (0.60) | AKT1LIMK2 | |
| SCHEMBL4917487 | 0.78 | AKT1 (0.70) | AKT1 | |
| SCHEMBL4776789 | 0.77 | AKT1 (0.62) | AKT1LIMK2KHKLRRK2CDC7 | |
| SCHEMBL4726005 | 0.77 | AKT1 (1.00) | AKT1 | |
| SCHEMBL4776768 | 0.77 | AKT1 (1.00) | AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | AKT1 752/4885LIMK2 1823/4885KHK 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.